A Phase 2 interventional study of Daratumumab in Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 17 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-14.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Lymphoma by Johnson & Johnson — none open to participants now, 1 under way, none of them phase 3. Lymphoma · Johnson & Johnson.
Among the 13 studies in Lymphoma by Johnson & Johnson, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2017, is one of 3 in phase 2, and was the 13th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 13 studies in Lymphoma by Johnson & Johnson is open now. The open studies under Lymphoma, anywhere →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 101 across the 10 interventional studies, 535 across the 3 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
1 of the studies in Lymphoma by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Lymphoma by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
Drug: Daratumumab
Participants will receive daratumumab 16 mg/kg as intravenous infusion.
Percentage of Participants With Overall Response
Overall response was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on blinded independent central review (BICR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), where applicable. CR: complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
Time frame: Up to 2 years and 11 months
Percentage of Participants With Complete Response (CR)
CR was defined as the percentage of participants who achieved CR as per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on BICR. CR was a complete disappearance of all evidence of disease.
Time frame: Up to 2 years and 11 months
Progression Free Survival (PFS)
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression/relapse or death, whichever came first. Progressive disease (PD) was defined as any new lesion greater than (\>) 1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50 percent (%) increase in previously involved sites.
Time frame: Up to 2 years and 11 months
Duration of Response (DoR)
DoR was defined as duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experienced CR). PD was defined as any new lesion \>1.5 cm in any axis or \>= 50% increase in previously involved sites.
Time frame: Up to 2 years and 11 months
Time to Response
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR based on BICR) is first documented. CR was defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
Time frame: Up to 2 years and 11 months
Overall Survival (OS)
OS was defined as the duration from the date of the first daratumumab dose to the date of death.
Time frame: Up to 2 years and 11 months
Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE were defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.
Time frame: Up to 2 years and 11 months
Number of Participants With Clinically Significant Change in Vital Signs
Number of participants with clinically significant change in vital signs (blood pressure, temperature, pulse rate, and weight) was reported.
Time frame: Up to 2 years and 11 months
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Number of participants with clinically significant ECG abnormalities were reported.
Time frame: Up to 2 years and 11 months
Number of Participants With Clinically Significant Change in Physical Finding
Number of participants with clinically significant change in physical finding was reported.
Time frame: Up to 2 years and 11 months
Number of Participants With Clinically Significant Change in Laboratory Parameters
Number of participants with clinically significant change in hematology (WBC, hemoglobin, platelets, neutrophils, and lymphocytes) and biochemistry (alanine transaminase \[ALT\], aspartate transaminase \[AST\], sodium, potassium, bilirubin, alkaline phosphatase, calcium laboratory parameters were reported.
Time frame: Up to 2 years and 11 months
| Milestone | Daratumumab |
|---|---|
| Started | 32 |
| Completed | 0 |
| Not completed | 32 |
| Withdrew: Death | 16 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Other | 3 |
| Withdrew: Disease progression at clinical cutoff | 1 |
Overall response was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on blinded independent central review (BICR). As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), where applicable. CR: complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
| percentage of participants | Daratumumab |
|---|---|
| Percentage of Participants With Overall Response | 25.0 (11.5 to 43.4) |
CR was defined as the percentage of participants who achieved CR as per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on BICR. CR was a complete disappearance of all evidence of disease.
| percentage of participants | Daratumumab |
|---|---|
| Percentage of Participants With Complete Response (CR) | 3.1 (0.08 to 16.22) |
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression/relapse or death, whichever came first. Progressive disease (PD) was defined as any new lesion greater than (\>) 1.5 centimeter (cm) in any axis or greater than or equal to (\>=) 50 percent (%) increase in previously involved sites.
| days | Daratumumab |
|---|---|
| Progression Free Survival (PFS) | 53.0 (43.0 to 106.0) |
DoR was defined as duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experienced CR). PD was defined as any new lesion \>1.5 cm in any axis or \>= 50% increase in previously involved sites.
| days | Daratumumab |
|---|---|
| Duration of Response (DoR) | 55.0 (29.0 to 339.0) |
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR based on BICR) is first documented. CR was defined as complete disappearance of all evidence of disease; PR as a greater than (\>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
| days | Daratumumab |
|---|---|
| Time to Response | 52.0 (49 to 57) |
OS was defined as the duration from the date of the first daratumumab dose to the date of death.
| days | Daratumumab |
|---|---|
| Overall Survival (OS) | 141.0 (94.0 to 235.0) |
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAE were defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.
| Participants | Daratumumab |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability | 26 |
Number of participants with clinically significant change in vital signs (blood pressure, temperature, pulse rate, and weight) was reported.
| Participants | Daratumumab |
|---|---|
| Number of Participants With Clinically Significant Change in Vital Signs | 0 |
Number of participants with clinically significant ECG abnormalities were reported.
| Participants | Daratumumab |
|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 2 |
Number of participants with clinically significant change in physical finding was reported.
| Participants | Daratumumab |
|---|---|
| Number of Participants With Clinically Significant Change in Physical Finding | 0 |
Number of participants with clinically significant change in hematology (WBC, hemoglobin, platelets, neutrophils, and lymphocytes) and biochemistry (alanine transaminase \[ALT\], aspartate transaminase \[AST\], sodium, potassium, bilirubin, alkaline phosphatase, calcium laboratory parameters were reported.
| Participants | Daratumumab |
|---|---|
| Hematology: WBC | 0 |
| Hematology: Hemoglobin | 0 |
| Hematology: Platelets | 0 |
| Hematology: Neutrophils | 0 |
| Hematology: Lymphocytes | 0 |
| Chemistry: ALT | 0 |
| Chemistry: AST | 0 |
| Chemistry: Sodium | 0 |
| Chemistry: Potassium | 0 |
| Chemistry: Bilirubin | 0 |
| Chemistry: Alkaline phosphatase | 0 |
| Chemistry: Calcium | 0 |
Collected over Up to 2 years and 11 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Daratumumab | 21/32 (65.6%) | 17/32 (53.1%) | 31/32 (96.9%) |
| Event | Daratumumab |
|---|---|
| PyrexiaGeneral disorders | 5/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/32 |
| Septic ShockInfections and infestations | 3/32 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/32 |
| CellulitisInfections and infestations | 2/32 |
| PneumoniaInfections and infestations | 2/32 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/32 |
| NeutropeniaBlood and lymphatic system disorders | 1/32 |
| Periorbital SwellingEye disorders | 1/32 |
| UveitisEye disorders | 1/32 |
| Event | Daratumumab |
|---|---|
| PyrexiaGeneral disorders | 20/32 |
| AnaemiaBlood and lymphatic system disorders | 9/32 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/32 |
| Alanine Aminotransferase IncreasedInvestigations | 9/32 |
| ChillsGeneral disorders | 8/32 |
| Aspartate Aminotransferase IncreasedInvestigations | 8/32 |
| HeadacheNervous system disorders | 8/32 |
| LeukopeniaBlood and lymphatic system disorders | 7/32 |
| NeutropeniaBlood and lymphatic system disorders | 7/32 |
| FatigueGeneral disorders | 7/32 |
All treated analysis set included all the participants who have received at least one dose of study drug.
| Age, Continuous(years) | Daratumumab |
|---|---|
| Mean | 54.8 ± 14 |
| Sex: Female, Male(Participants) | Daratumumab |
|---|---|
| Female | 9 |
| Male | 23 |
| Ethnicity (NIH/OMB)(Participants) | Daratumumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Daratumumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 32 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Daratumumab |
|---|---|
| CHINA | 7 |
| HONG KONG | 1 |
| REPUBLIC OF KOREA | 17 |
| SINGAPORE | 2 |
| TAIWAN, PROVINCE OF CHINA | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jan 2020, 34 months.
Results were first posted in Jan 2021, 1 year after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 34 months is close to that.
Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →